Skip to main content
. 2023 Jan 27;12(3):422. doi: 10.3390/cells12030422

Figure 5.

Figure 5

Imatinib increases un-phosphorylated (active form) CRKL in HBMECs. (A) Western blot shows decreased expressions of pCRKL in HBMECs after imatinib treatment. (B) Statistical analysis of total and phosphorylated CRKL indicates that the protein level of total CRKL is not affected by imatinib treatment (p > 0.21, linear mixed model ANOVA test), while pCRKL level is significantly reduced (* p < 0.006, linear mixed model ANOVA test). (C) Comparison of pCRKL to total CRKL indicates that this ratio is significantly decreased after imatinib treatment (* p < 0.001).